Clinical trials: sponsored by Fudan University
Microsatellite Stable Metastatic Colorectal Cancer
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
The study compares the efficacy and safety of regorafenib alone or in combination with hypofractionated radiotherapy and low-dose radiotherapy (LDRT) plus toripalimab in patients with microsatellite stable metastatic colorectal…
- Trial name
- SLOT (NCT05963490)
- Testing
- Regorafenib, Toripalimab, Radiotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Fudan University
Pancreatic Cancer
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from clinically-annotated individuals.
- Trial name
- NCT06166147
- Where
- 3 sites in China
- Volunteers
- 276 people
- Sponsor
- Fudan University
Solid Tumour
ADC-induced Neurotoxicity Treated With Duloxetine
RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is effective in treating peripheral neuropathy caused by antibody-drug conjugate.
- Trial name
- NCT06551051
- Testing
- duloxetine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Breast Neoplasms
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
1. To construct a prospective, multi-center breast cancer treatment cohort in China, and analyze the factors affecting breast cancer diagnosis and treatment. 2.
- Trial name
- NCT06591039
- Testing
- The study did not involve intervention in the patient's treatment regimen
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Fudan University
NMIBC
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC)…
- Trial name
- NCT06588179
- Testing
- SHR-1501+SHR-2005
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Primary Liver Cancer, Colorectal Cancer Liver Metastases
Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors
This single-center, parallel-controlled clinical trial aims to establish a multi-mode ablation system for liver malignant tumors originating from the digestive system.
- Trial name
- NCT06588569
- Testing
- Multi-mode tumor treatment system, Radiofrequency ablation therapeutic apparatus
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Solid Tumor
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors
Multicenter, single arm, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (BEN101) followed by IL-2 after a…
- Trial name
- NCT05831033
- Testing
- BEN101
- Where
- 3 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CRC, MSS
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
This is a prospective, single-arm, single-center Phase II clinical study. In this study, participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy.
- Conditions
- CRC, MSS, Metastatic Cancer
- Trial name
- NCT06593548
- Testing
- Ivosidenib (AK112)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fudan University
Mantle Cell Lymphoma, Maintenance Therapy
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
This study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell lymphoma who had remission after first-line…
- Trial name
- NCT06341556
- Testing
- Zanubrutinib
- Where
- 2 sites in China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Lung Adenocarcinoma, Surgical Procedure, Unspecified
Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014)
This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1014). The goal of this clinical trial is to confirm the concordance rate between intra-operative frozen section pathological diagnosis and post-operative…
- Conditions
- Lung Adenocarcinoma, Surgical Procedure, Unspecified, Pathology
- Trial name
- NCT05794698
- Testing
- Surgical resection
- Where
- China
- Volunteers
- 827 people
- Sponsor
- Fudan University
Breast Cancer
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
This study will evaluate the safety, tolerability and efficacy of anlotinib and trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-low unresectable and/or metastatic breast cancer who had received ≤1 line…
- Trial name
- NCT06331169
- Testing
- Anlotinib, Trastuzumab deruxtecan
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Breast Cancer Stage IV
Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer
This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic…
- Trial name
- NCT06578299
- Testing
- Inetetamab and Paclitaxel ± Pertuzumab
- Volunteers
- 100 people
- Sponsor
- Fudan University
Breast Cancer
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A single arm, phase 2 Study of ARX788 in HER2-positive metastatic breast cancer patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
- Trial name
- NCT06578286
- Testing
- ARX788
- Volunteers
- 44 people
- Sponsor
- Fudan University
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Esophageal Carcinoma Salivary Gland Type, Radiotherapy
The Study on the Mechanism of Radiotherapy-elicited Immune Response
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. Data from many laboratories indicate that local radiation produces systemic, immune-mediated anti¬tumour and, potentially, antimetastatic…
- Trial name
- NCT06393140
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Congenital Microtia
Application and Effectiveness of the Perioperative Position Management Based on the ADDIE Model in Patients With Congenital Microtia
Aims and objectives: To evaluate the clinical application and effectiveness of a perioperative position management program constructed using the ADDIE model for patients with congenital microtia.
- Trial name
- NCT06569927
- Testing
- Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.
- Where
- China
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Eye & ENT Hospital of Fudan University
3-year Disease-free Survival
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
- Trial name
- NCT06561620
- Testing
- Befotertinib
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Fudan University
Postpartum Depression
Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients
Postpartum depression is a common psychological abnormality during the puerperium, which seriously affects maternal and neonatal health.
- Trial name
- NCT05826327
- Testing
- Esketamine, Sufentanil
- Where
- China
- Volunteers
- 364 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Pancreatic Neoplasms, Mediastinal Neoplasms
22G-Adapt Needle Biopsy Versus Fine-needle Aspiration in Endoscopic Ultrasound-guided Sampling of Solid Lesions
The investigators conduct a multicenter randomized controlled study to evaluate the diagnostic value and safety of 22G Adapt Aspiration puncture needle for histopathology of solid lesions.
- Conditions
- Pancreatic Neoplasms, Mediastinal Neoplasms, Abdominal Neoplasm, Excluding Pancreas Neoplasm
- Trial name
- NCT06563232
- Testing
- FNA group, Adapt FNB group
- Where
- China
- Volunteers
- 656 people
- Sponsor
- Huazhong University of Science and Technology
NSCLC Stage IV, EGFR Activating Mutation
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) for patients with oligo-residual NSCLC after 3rd generation EGFR-TKIs.
- Trial name
- NCT04764214
- Testing
- 3rd generation EGFR-TKI, Consolidative SRT
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.